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Interleukin-18, neutrophils, and 
ANCA
BM Pressler, RJ Falk and CA Preston
Hewins et al. show that IL-18 is expressed in the kidneys of patients with 
ANCA-associated glomerulonephritis, and that IL-18 primes neutrophils 
via p38 MAPK. These findings suggest a role for IL-18, including IL-18-
induced TH1 polarization and IFN-γ production, in the progression of 
ANCA disease.
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Each cytokine produces a range of cel-
lular responses, dependent on cell type, 
presence of other modulating cytokines, 
and other components of the infl amma-
tory milieu. Interleukin-18 (IL-18) was 
initially named interferon-γ (IFN-γ)-
inducing factor, because it was shown 
to induce production of IFN-γ by 
splenocytes (particularly in the pres-
ence of lipopolysaccharide).1 We now 
know that this is due to IL-18’s role in 
polarization of naive T cells to a T helper 
type 1 (Th 1) response, and subsequent 
production by these T cells of IFN-γ.2 
IL-18 alone is suffi  cient to induce IFN-
γ production by naive T cells, but this 
eff ect is signifi cantly amplifi ed in the 
presence of IL-12 — not surprising, as 
IL-12 is the most potent Th 1-polarizing 
cytokine described and, in addition, 
upregulates expression of the IL-18 
receptor on T cells.3 Th ere is still a large 
amount of handwaving as to why some 
pathogens induce an IL-12/IL-18/Th 1-
polarizing response whereas others pref-
erentially lead to an IL-4/Th 2-polarizing 
response, but the prevailing thought is 
that this depends on the particular set 
of cytokines induced by a pathogen’s 
binding to a particular subset of pattern-
recognition receptors, such as Toll-like 
receptors. IL-18 may also play a role 
in some instances of Th 2 polarization, 
particularly in the presence of NK T-cell 
production of IL-4, although this is not 
as clear.2
IL-18 is constitutively secreted by 
monocytes, macrophages, and den-
dritic cells as the inactive precursor 
pro-IL-18; other cell types have been 
shown to produce pro-IL-18 as well, but 
whether this also occurs constitutively is 
unclear.2 Pro-IL-18 is activated by enzy-
matic cleavage by caspase-1, but other 
proteases can activate IL-18 in vitro, 
including proteinase 3, a component of 
neutrophil and monocyte azurophilic 
granules.4 Th e IL-18 receptor is a het-
erodimer that associates aft er the IL-18R 
α chain binds activated IL-18. Signal 
transduction occurs through the IL-18 
receptor β chain by several intracellular 
pathways, including p38 mitogen-acti-
vated protein kinase.2
Hewins et al. report in this issue of 
KI that IL-18 is capable of priming 
neutrophils in vitro, thus augmenting 
superoxide production by cells after 
antineutrophil cytoplasmic antibody 
(ANCA) binding.5 Th is increased activ-
ity is similar to that seen with tumor 
necrosis factor-α priming, the favored 
method for most ex vivo experiments 
studying the effects of ANCA. The 
authors also demonstrate that neu-
trophil priming occurs via p38 mitogen-
activated protein kinase activation, and 
that IL-18 and tumor necrosis factor-α 
may be synergistic at lower concentra-
tions. In addition, increased IL-18 was 
found in podocytes, distal tubular epi-
thelial cells, and interstitial myofi brob-
lasts and macrophages in renal biopsies 
from patients with ANCA-associated 
glomerulonephritis. These findings 
suggest that an IL-18-induced immune 
response may play a role in intravas-
cular activation of neutrophils prior to 
degranulation, or that ANCA produc-
tion and tissue damage may be main-
tained by Th 1 cells.
But what does this truly mean or 
imply in ANCA-associated glomeru-
lonephritis? Unfortunately, although 
production of anti-proteinase 3 or anti-
myeloperoxidase immunoglobulin G 
implies the presence of antigen-specifi c 
T cells that have participated in B-cell 
clonal expansion, affi  nity maturation, 
and isotype switching, T cells specifi c 
for these granule proteins have not been 
reliably demonstrated in patients with 
ANCA disease.6 Th ere is, however, evi-
dence (albeit oft en confl icting) that both 
Th 1- and Th 2-mediated T-cell responses 
are involved in ANCA disease. Periph-
eral blood and intralesional T cells 
from patients with localized Wegener’s 
granulomatosis are predominantly CD4+ 
IFN-γ-secreting cells, whereas T cells 
from patients with Churg-Strauss syn-
drome are predominantly CD4+ IL-4-
secreting cells; Th 1 and Th 2 cytokine 
secretion patterns have been reported in 
T cells from patients with microscopic 
polyangiitis.7,8 To confuse matters even 
more, T cells from patients with ANCA 
disease may have altered phenotypes 
(expansion in CD28– cells) or may alter 
their cytokine secretion patterns as dis-
ease progresses (T cells in generalized 
Wegener’s granulomatosis show a shift  
to a Th 2 pattern).7,8
Th e fi ndings reported by Hewins et 
al.5 therefore add to our understanding 
of the Th 1/Th 2 and cytokine dysregula-
tion in ANCA disease. We can speculate 
that the fi nding of IL-18 in renal tissue 
from patients with ANCA disease, and 
the ability of this cytokine to prime 
neutrophils, demonstrate that Th1-
mediated responses may be involved in 
disease progression. However, several 
additional questions arise from these 
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fi ndings. If the podocytes are the pri-
mary excreters of IL-18, where are the 
activated Th 1 cells? What is the stimulus 
for production and secretion of IL-18? 
Are the podocytes and other renal cells 
perhaps endocytosing IL-18 rather than 
producing it? Alternatively, we must ask 
whether IL-18 production by these cells 
is instead a consequence rather than an 
initiator of neutrophil activation. As 
we know that proteinase 3 is capable of 
activating pro-IL-18 in vitro, what are 
the functional consequences of this in 
proteinase 3-ANCA disease? It would 
be expected that any cytokine secreted 
by podocytes would pass into the urine 
rather than cross the glomerular base-
ment membrane opposite to the normal 
direction of fi ltration; direct secretion by 
the podocytes into the vasculature would 
truly be a novel finding. Regardless, 
this report reveals that podocytes may 
be direct participators in the immune 
dysfunction of ANCA disease, and that 
IL-18 may be responsible for neutrophil 
priming in vivo.
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Fibroblast growth factor 23: the 
making of a hormone
SC Schiavi1
Fibroblast growth factor 23 (FGF23) modulates serum phosphate and 
1α,25-dihydroxyvitamin D3 levels.  FGF23 expression is in turn regulated 
by 1α,25-dihydroxyvitamin D3 and dietary phosphate load, and is 
strikingly elevated during renal progression.   In this issue, Nagano and 
colleagues report that FGF23 can be modulated by intermittently high 
dietary phosphate in the presence of compromised renal function.  
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Over the past several years, accumulat-
ing evidence has documented the role of 
fi broblast growth factor 23 (FGF23) in 
the control of phosphate and vitamin D 
homeostasis. Th ese data show that FGF23 
acts in accordance with the defi nition of a 
hormone: a circulating protein that targets 
specifi c tissues distant from its site of pro-
duction. FGF23 acts directly on the kidney 
to regulate the synthesis of 1α,25-dihy-
droxyvitamin D3 and the surface expres-
sion of the sodium phosphate transporters 
NaPi-IIa and -IIc.1–4 Several reports now 
demonstrate that serum FGF23 con-
centrations increase both in response to 
dietary phosphate load with normal renal 
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function and in response to increasing 
serum phosphate levels associated with 
progressive renal failure.1,3 Despite this 
body of data, a debate continues regard-
ing the physiological relevance of FGF23 
as a major regulator of phosphate home-
ostasis. In particular, it has been argued 
that elevated FGF23 in renal disease is a 
consequence of reduced renal clearance 
and therefore may not play a direct role 
in the progression of renal disease and its 
associated complications.
The study presented in this issue by 
Nagano et al.5 represents an important 
advancement beyond the previously 
identifi ed association of elevated FGF23, 
phosphate, and parathyroid hormone 
(PTH) levels in renal disease.1,3,4 By using 
a model of severe chronic kidney disease 
and including an experimental arm in 
which phosphate levels were regulated 
by intermittent dosing of the phosphate 
binder sevelamer hydrochloride, the 
authors have provided convincing evi-
dence that FGF23 serum concentrations 
were infl uenced by elevated dietary and 
serum phosphate. Importantly, the data 
argue that decreased renal function can-
not adequately explain the dramatic rise 
in FGF23 serum concentrations associ-
ated with renal insuffi  ciency, as changes 
in serum FGF23 levels were observed in 
the presence of severely compromised kid-
ney function. Together with the substan-
tial data demonstrating direct actions of 
FGF23 on renal phosphate excretion, these 
results imply that the levels of FGF23, like 
those of PTH, may rise in response to the 
increasing pressure to excrete phosphate.
Th e study by Nagano et al.5 also dem-
onstrates another important feature of 
FGF23 regulation: that FGF23 serum 
levels are modified rather slowly in 
response to increased dietary phosphate. 
Although changes in serum phosphate 
and PTH occurred 1 day after sevela-
mer treatment or removal, there was an 
additional lag before FGF23 levels were 
altered. Th e mechanism triggering the 
slow regulation of FGF23 is not clear, but 
the delay suggests that phosphate does 
not directly control FGF23 synthesis. 
Th is result implies that FGF23’s function 
is most important as a chronic rather than 
an acute response to changes in phos-
phate and partially explains the need for 
